CompletedNCT01073982Updated Jan 20, 2011

Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis

A Phase 4 interventional study of tart cultivar Montmorency cherry juice in Pain and Inflammation, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-01-20.

Sponsored by Oregon Health and Science University · Phase 4, Interventional, and Treatment

Phase: Phase 4
Study type: Interventional
Enrollment: 20
Allocation: Randomized
Ages: 30 Years to 70 Years
Sex: All

Study summary

The purpose of this study is to assess the effects of tart cherry juice to reduce pain and inflammation among individuals with arthritis.

Read the detailed description

Numerous antioxidant and anti-inflammatory agents have been identified in tart cherries, and a study among healthy, non-exercising individuals demonstrated that cherry consumption decreased serum inflammatory biomarkers after 14 days. Osteoarthritis (OA) is a common syndrome affecting 65 million Americans characterized by pain, inflammation, and disability. Such natural anti-inflammatory effects of cherry consumption may be beneficial for the management and treatment of osteoarthritis and inflammatory diseases. The purpose of this randomized, double-blind, placebo controlled study is to examine individuals with inflammatory OA and assess the analgesic and anti-inflammatory effects of tart cherry juice as compared to a placebo drink among twenty 30-70 y/o OA subjects.

Conditions studied

Pain
Inflammation

Browse trials for

Keywords

pain
inflammation
osteoarthritis

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's planned enrollment of 20 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 30 Years to 70 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Diagnosed with inflammatory osteoarthritis
In good general health
Stable pattern of anti-inflammatory or pain relieving drug use for 3 months prior to study
Ability and willingness to maintain consistent pattern of anti-inflammatory or pain relieving drug use during the course of the study, and to not seek any other treatment during the study
Ability and willingness to consume juice or placebo drink for 21 consecutive days, and to participate in screening measures, including a blood draw, before and after the intervention period

Exclusion criteria

Exclusion Criteria:

Pregnancy
Serious medical conditions such as recent heart attack or stroke, cancer, diabetes (type 1 and type 2), or gastrointestinal ulcers
Individuals who have not been on a stable dose of pain medications or pain modalities for at least 3 months, including muscle relaxants, tender point anesthetic injections, systemic or intrabursal or intraarticular steroids, or any investigational drug/device in the prior 90 days
Individuals who have used nonpharmacologic pain therapies including acupuncture, ultrasound, or transcutaneous electrical nerve stimulation within the past 30 days

Study design

Phase: Phase 4
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Triple (Participant, Investigator, Outcomes assessor)
Enrollment: 20 participants (estimated)

Study arms

Placebo comparator
cherry flavored fruit drink
Dietary Supplement: tart cultivar Montmorency cherry juice
Experimental
tart cherry juice
Dietary Supplement: tart cultivar Montmorency cherry juice

Interventions

Dietary supplementtart cultivar Montmorency cherry juice
21 ounces of experimental or placebo juice, consumed daily for 21 days.

What researchers measure

Primary outcomes

Primary outcomes include measurement of interleukin 10 (IL-10), CRP, and a specific group of cytokines that provide a generalized measurement of inflammatory activity, these include IL-6 and TNF-α.
Time frame: 6-8 months

Study locations

1 site

Oregon Health and Science University
Portland, Oregon 97239, United States

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jan 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01073982
Lead sponsor: Oregon Health and Science University
Collaborators: Cherry Research Committee
First posted: Feb 24, 2010
Start date: Feb 2010
Primary completion: Jan 2011
Completion: Jan 2011
Last update: Jan 20, 2011

Study contacts

Kerry S Kuehl, MD, PhD

principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Osteoarthritis→

Other studies from this sponsor

Oregon Health and Science University

Start the discussion